ClinicalTrials.gg

Program

BTK Inhibitor TT-01488

Also written as “TT-01488 Tablets” and “TT-01488”.

Its studies are mostly in Lymphoma, Mantle-Cell, led by TransThera Sciences (Nanjing).

Furthest: phase 2, since Sep 21, 20263 company-led studies, 2 open or runningNext primary completion: Oct 10, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TransThera Sciences (Nanjing)32 open or runningphase 2since Sep 21, 2026Feb 21, 2022Oct 10, 2029phase 2 · NCT07855016

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 21, 2022First study: phase 1 study in B-Cell MalignanciesFirst studyNCT05275504 · 37 enrolled · United States
  2. Jan 4, 2023Phase 1 study in B-Cell MalignanciesNCT05683717 · 37 planned · China
  3. Sep 21, 2026Phase 2 study in Lymphoma, Mantle-CellPhase 2 reachedNCT07855016 · 188 planned · China

Ahead

  1. Oct 10, 2029Primary completion: phase 2 study in Lymphoma, Mantle-CellNCT07855016

TargetBeta

BTK →read by rule
“An orally bioavailable reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07855016Lymphoma, Mantle-Cell · China2Not yet recruitingOct 10, 2029188
NCT05683717B-Cell Malignancies · China1RecruitingOct 31, 202637
NCT05275504B-Cell Malignancies · United States1UNKNOWNSep 202237

How it is read

Names in the registry

  • “TT-01488 Tablets”, 2 entries
  • “TT-01488”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.